Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

Next Previous
Trial Profile

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enlicitide decanoate (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

Most Recent Events

  • 06 Mar 2023 According to a Merck & Co media release, Dr.Christie M. Ballantyne is a principal investigator of this study.
  • 06 Mar 2023 Primary endpoint (Percent Change from Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8) has been met, according to Merck & Co media release.
  • 06 Mar 2023 According to a Merck & Co media release, results of this study were presented at American College of Cardiology's 72nd Annual Scientific Session together with World Congress of Cardiology (ACC.23/WCC) and simultaneously published in the Journal of The American College of Cardiology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top